vTv Therapeutics (VTVT) Revenue (2014 - 2026)

vTv Therapeutics has disclosed Revenue across 11 years of filings, most recently posting $36.8 million for Q1 2026.

• Revenue for Q1 2026 came in at $36.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $36.8 million (up 216600.0% YoY), and the FY2024 annual result was $1.0 million, changed N/A from the prior year.
• Revenue came in at $36.8 million for Q1 2026 at vTv Therapeutics, up from $17000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $36.8 million in Q1 2026 to a low of $9000.0 in Q2 2022.
• The 3-year median for Revenue is $508500.0 (2024), against an average of $6.6 million.
• Peak annual rise in Revenue reached 102.63% in 2022, while the deepest fall reached 0.0% in 2022.
• vTv Therapeutics' Revenue stood at $9000.0 in 2022, then jumped by 88.89% to $17000.0 in 2024, then jumped by 216600.0% to $36.8 million in 2026.
• The last three Revenue figures came in at $36.8 million (Q1 2026), $17000.0 (Q4 2024), and $1.0 million (Q1 2024), per Business Quant data.